Next Article in Journal
Correlation between Three-Dimensional Volume and Malignant Potential of Gastrointestinal Stromal Tumors (GISTs)
Next Article in Special Issue
Enhanced Medical and Community Face Masks with Antimicrobial Properties: A Systematic Review
Previous Article in Journal
Improvement in Contrast Sensitivity Function after Lacrimal Passage Intubation in Eyes with Epiphora
Previous Article in Special Issue
SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches—Insights into Chemical Structure—Biological Activity and Toxicological Screening
Review

Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients?

1
Maria Cecilia Hospital, GVM Care & Research, 48033 Cotignola (RA), Italy
2
Department of Morphology, Experimental Medicine and Surgery, University of Ferrara, via Fossato di Mortara 70, 44121 Ferrara, Italy
3
Department of Cardiac Surgery Pompidou Hospital, Laboratory of Biosurgical Research, Carpentier Foundation, University Paris Descartes, 75015 Paris, France
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(9), 2762; https://doi.org/10.3390/jcm9092762
Received: 7 August 2020 / Accepted: 25 August 2020 / Published: 26 August 2020
Coronavirus disease 2019 (COVID-19) is a pandemic viral disease originated in Wuhan, China, in December 2019, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The severe form of the disease is often associated with acute respiratory distress syndrome (ARDS), and most critically ill patients require mechanical ventilation and support in intensive care units. A significant portion of COVID-19 patients also develop complications of the cardiovascular system, primarily acute myocardial injury, arrhythmia, or heart failure. To date, no specific antiviral therapy is available for patients with SARS-CoV-2 infection. Exosomes derived from mesenchymal stem cells (MSCs) are being explored for the management of a number of diseases that currently have limited or no therapeutic options, thanks to their anti-inflammatory, immunomodulatory, and pro-angiogenic properties. Here, we briefly introduce the pathogenesis of SARS-CoV-2 and its implications in the heart and lungs. Next, we describe some of the most significant clinical evidence of the successful use of MSC-derived exosomes in animal models of lung and heart injuries, which might strengthen our hypothesis in terms of their utility for also treating critically ill COVID-19 patients. View Full-Text
Keywords: coronavirus; COVID-19; angiotensin-converting enzyme 2; mesenchymal stem cell-derived exosomes; acute lung injury; acute myocardial injury; immunomodulation; anti-inflammation coronavirus; COVID-19; angiotensin-converting enzyme 2; mesenchymal stem cell-derived exosomes; acute lung injury; acute myocardial injury; immunomodulation; anti-inflammation
Show Figures

Figure 1

MDPI and ACS Style

Gardin, C.; Ferroni, L.; Chachques, J.C.; Zavan, B. Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients? J. Clin. Med. 2020, 9, 2762. https://doi.org/10.3390/jcm9092762

AMA Style

Gardin C, Ferroni L, Chachques JC, Zavan B. Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients? Journal of Clinical Medicine. 2020; 9(9):2762. https://doi.org/10.3390/jcm9092762

Chicago/Turabian Style

Gardin, Chiara, Letizia Ferroni, Juan C. Chachques, and Barbara Zavan. 2020. "Could Mesenchymal Stem Cell-Derived Exosomes Be a Therapeutic Option for Critically Ill COVID-19 Patients?" Journal of Clinical Medicine 9, no. 9: 2762. https://doi.org/10.3390/jcm9092762

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop